Insiders who reported open-market trades in the last 12 months at the companies Richard A. Paulson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Stuart Poulton - $56K in KPTI purchases and sales in the last 12 months
Reshma Rangwala - $56K in KPTI purchases and sales in the last 12 months
Richard A. Paulson is a corporate insider, tracked as President and CEO of Karyopharm Therapeutics Inc. (KPTI). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Richard A. Paulson last file a Form 4?
The most recent primary Form 4 on record is dated 15 May 2026, one of 9 filings going back to 2024.
Has Richard A. Paulson been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($155K) across all tracked filings.
Richard A. Paulson is President and CEO of Karyopharm Therapeutics Inc. (KPTI). 9 SEC Form 4 filings on record going back to 2024, most recently on 15 May 2026. Most recent open-market trade: sold $21K of KPTI on 15 May 2026. Lifetime open-market sales: $155K.
Recent transactions
11
The latest 11 SEC Form 4 transactions reported by Richard A. Paulson.
InsiderAlpha's records for Richard A. Paulson go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
